Nanotemplate Engineering

Nanotemplate Engineering is a scaleable nanoparticle manufacturing technology that enables the delivery of small molecules, peptides, proteins, plasmid DNA, and diagnostic agents. Nanotemplate Engineering technology is used to routinely and cost-effectively produce nanoparticles that: (1) mask the delivery-limiting characteristics of given drugs; and (2) enable targeted delivery of drugs to specific tissues and cells (e.g. tumors). Other nanoparticle technologies have not demonstrated an ability to achieve such pharmacokinetic and pharmacodynamic attributes. As a drug delivery technology, Nanotemplate Engineering can also provide a sustained release of drugs in tissues, which can reduce dosage frequency, peripheral toxicity, and adverse effects; and can enhance efficacy, expand the indications for which a drug may be prescribed, and provide new patent-protection for current or soon-to-be off-patent drugs. Nanotemplate Engineering technology has been the subject of more than 35 peer-reviewed scientific publications authored by NanoMed's co-founders, Russell J. Mumper, Ph.D. and Michael Jay, Ph.D.  NanoMed has the exclusive rights to U.S. Patent 7,153,525 (“Microemulsions As Precursors To Solid Nanoparticles”) which covers processes and applications of Nanotemplate Engineering.